HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
Contact: Study coordinator (wu liming Wu, Doctor of Medicine) · 18957118053@163.com · 0571-56005600

Study leads

Wu Liming NA, Doctor of Medicine
Principal Investigator
First People's Hospital of Hangzhou

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Study to Evaluate SM17 for Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE2

Beijing, China

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

The Bronx, United States

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · North Little Rock, United States